Generation of three-dimensional cluster entangled state

Measurement-based quantum computing is a promising paradigm of quantum computation, where universal computing is achieved through a sequence of local measurements. The backbone of this approach is the preparation of multipartite entanglement, known as cluster states. While a cluster state with two-dimensional (2D) connectivity is required for universality, a three-dimensional (3D) cluster state is necessary for additionally achieving fault tolerance. However, the challenge of making 3D connectivity has limited cluster state generation up to 2D. Here we experimentally generate a 3D cluster state in the continuous-variable optical platform. To realize 3D connectivity, we harness a crucial advantage of time-frequency modes of ultrafast quantum light: an arbitrary complex mode basis can be accessed directly, enabling connectivity as desired. We demonstrate the versatility of our method by generating cluster states with 1D, 2D, and 3D connectivities. For their complete characterization, we develop a quantum state tomography method for multimode Gaussian states. Moreover, we verify the cluster state generation by nullifier measurements, as well as full inseparability and steering tests. Finally, we highlight the usefulness of 3D cluster state by demonstrating quantum error detection in topological quantum computation. Our work paves the way toward fault-tolerant and universal measurement-based quantum computing

Implementing a Fitness and Nutrition Program for Special Olympics Athletes

Introduction: Only 17-30% of individuals with ID meet the recommendations for daily exercise Populations of individuals with ID have higher BMI, lower cardiovascular fitness and lower muscle strength compared to the general population Individuals with ID also have many dietary challenges necessitating nutritional education and interventions One study following four athletes with ID, showed that pairing athletes with and without (unified sports) resulted in a positive change in social self-concept for athletes with ID Given the above, we: Created a 6-week pilot training and nutrition program for Special Olympics Vermont (SOVT). Paired athletes with ID with college athletes without ID to promote wellness during the athlete’s off season.https://scholarworks.uvm.edu/comphp_gallery/1229/thumbnail.jp

Radioembolization Is a Safe and Effective Treatment for Hepatocellular Carcinoma with Portal Vein Thrombosis: A Propensity Score Analysis

<div><p>Background/Aims</p><p>Limited treatment options are available for patients with hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT). Transarterial radioembolization using Yttrium-90 microspheres is a new treatment modality for HCC with PVT. For this analysis, we compared responses to treatment with radioembolization and with sorafenib.</p><p>Methods</p><p>We evaluated 32 patients who were part of a multicenter retrospective cohort. All patients had PVT without extrahepatic metastasis and were treated with radioembolization in one of six tertiary referral hospitals in Korea. We retrospectively enrolled another 31 consecutive PVT patients without extrahepatic metastasis from a single center who received sorafenib treatment to serve as the control group. We used inverse probability weighting (IPW) using propensity scores to adjust for the between-group differences in baseline characteristics.</p><p>Results</p><p>At 3 months, the response rate and disease control rate were 32.1% (9/32) and 57.1% (16/32), respectively, in the radioembolization group and 3.2% (1/31) and 41.9% (13/31) in the sorafenib group. Median overall survival (OS) and time to progression (TTP) were not significantly different between the radioembolization group and the sorafenib group (13.8 months and 10.0 months, P = 0.22; and 6.0 months and 6.0 months, P = 0.08; respectively). No differences in OS (P = 0.97) or TTP (P = 0.34) were observed after IPW was applied to balance the population characteristics. The sorafenib group showed significantly more grade 3/4 adverse effects than the radioembolization group (P < 0.01).</p><p>Conclusion</p><p>HCC patients with PVT who underwent radioembolization achieved comparable survival to patients who received sorafenib, even after application of IPW. The radioembolization group also experienced fewer severe adverse effects. Radioembolization can be considered a new treatment option for patients with HCC with PVT.</p></div

Response to treatment.

<p>Response to treatment.</p

Baseline characteristics of patients with portal vein thrombosis and without extrahepatic metastasis.

<p>Baseline characteristics of patients with portal vein thrombosis and without extrahepatic metastasis.</p

Adverse effects according to CTCAE ver 4.03.

<p>Adverse effects according to CTCAE ver 4.03.</p